Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A genetic model of ivabradine recapitulates results from randomized clinical trials.

PloS one - 1 Jan 2020

Legault Marc-André, Sandoval Johanna, Provost Sylvie, Barhdadi Amina, Lemieux Perreault Louis-Philippe, Shah Sonia, Lumbers R Thomas, de Denus Simon, Tyl Benoit, Tardif Jean-Claude, Dubé Marie-Pierre

Abstract excerpt

BACKGROUND: Naturally occurring human genetic variants provide a valuable tool to identify drug targets and guide drug prioritization and clinical trial design. Ivabradine is a heart rate lowering drug with protective effects on heart failure despite increasing the risk of atrial fibrillation. In patients with coronary artery disease without heart failure, the drug does not protect against major cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Endpoint Determination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Rate

Share to Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels

Share to Mendelian Randomization Analysis

Share to Muscle Proteins

Share to Potassium Channels

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 32692755
DOI: 10.1371/journal.pone.0236193
PMCID: PMC7373274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A genetic model of ivabradine recapitulates results from randomized clinical trials.PMID 32692755Read ↗

A genetic model of ivabradine recapitulates results from randomized clinical trialsSemantic proximity Read ↗

Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: A preliminary report.Semantic proximity Read ↗

Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations.Semantic proximity Read ↗

Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patientsSemantic proximity Read ↗

Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.Semantic proximity Read ↗

Genetic variants related to antihypertensive targets inform drug efficacy and side effectsSemantic proximity Read ↗

Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.Semantic proximity Read ↗

Combining Genetic Proxies of Drug Targets and Time-to-event analyses From Longitudinal Observational Data To Identify Target Patient PopulationsSemantic proximity Read ↗

Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatmentSemantic proximity Read ↗

Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation.Semantic proximity Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.